Beta Drugs- CONSOL HY1-FY21 PAT jumps to Rs.5.18 crore against PAT of Rs.5.12 crore in HY1-FY20.
Beta Drugs- Standalone HY1-FY21 PAT of Rs.3.06 crore against of profit Rs.4 crore in HY1-FY20.
Company : Beta Drugs Limited
Beta Drugs announced its standalone and consolidated financials for the half year ended on 30th September, 2020 marking a decline in standalone post-tax gains as compared to a year ago period.
Following are the standalone financial figures for the HY1-FY2021:- Net profit stood at Rs.3.06 crore against profit of Rs.4 crore in a year ago period. - Revenue reached Rs.35.09 crore whereas last year corresponding period it was Rs.34.35 crore. - Earning per share stood at Rs. 3.18 against EPS of Rs.4.29 in the previous year, same period.
For the year that ended on 31st March, 2020, the company earned standalone total revenue of Rs.65.73 crore with net profit of Rs.7.09 crore and Earning per share of Rs. 7.49.
Consolidated HY1 financials at Beta Drugs in FY2020-21 are as follows:- Net Profit reached at Rs.5.18 crore against PAT of Rs.5.12 crore in a year ago period - Revenue stood at Rs.51.63 crore while previous year same period it was Rs.46.80 crore - Earning per share stood at Rs. 5.39 against EPS of Rs. 5.48 in the previous year, same period.
Annual consolidated PAT for FY19-20 reached Rs.9.41 crore with revenue of Rs.91.21 crore and Earning per share of Rs.9.93.